| Literature DB >> 28487436 |
Eoin Brennan1,2, Bo Wang1,3, Aaron McClelland1, Muthukumar Mohan1,4, Mariam Marai2, Ophelie Beuscart1, Sinda Derouiche1, Stephen Gray1, Raelene Pickering1,4, Chris Tikellis1,4, Monica de Gaetano2, Mary Barry5, Orina Belton6, Syed Tasadaque Ali-Shah7, Patrick Guiry7, Karin A M Jandeleit-Dahm1,4, Mark E Cooper1,4, Catherine Godson2, Phillip Kantharidis8,4.
Abstract
The let-7 miRNA family plays a key role in modulating inflammatory responses. Vascular smooth muscle cell (SMC) proliferation and endothelial cell (EC) dysfunction are critical in the pathogenesis of atherosclerosis, including in the setting of diabetes. Here we report that let-7 levels are decreased in diabetic human carotid plaques and in a model of diabetes-associated atherosclerosis, the diabetic ApoE-/- mouse. In vitro platelet-derived growth factor (PDGF)- and tumor necrosis factor-α (TNF-α)-induced vascular SMC and EC activation was associated with reduced let-7 miRNA expression via Lin28b, a negative regulator of let-7 biogenesis. Ectopic overexpression of let-7 in SMCs inhibited inflammatory responses including proliferation, migration, monocyte adhesion, and nuclear factor-κB activation. The therapeutic potential of restoring let-7 levels using a let-7 mimic was tested: in vitro in SMCs using an endogenous anti-inflammatory lipid (lipoxin A4), ex vivo in murine aortas, and in vivo via tail vein injection in a 24-h murine model. Furthermore, we delivered let-7 mimic to human carotid plaque ex vivo and observed significant changes to the secretome in response to let-7 therapy. Restoration of let-7 expression could provide a new target for an anti-inflammatory approach in diabetic vascular disease.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28487436 DOI: 10.2337/db16-1405
Source DB: PubMed Journal: Diabetes ISSN: 0012-1797 Impact factor: 9.461